InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,232.78
(
1.03%
)
Post# of 252496
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

ocyanblue

Send PM Follow Ignore
Followers 0
Posts 167
Boards Moderated 0
Alias Born 03/28/2005

ocyanblue

Re: DewDiligence post# 36427

Saturday, 10/28/2006 8:18:17 PM

Saturday, October 28, 2006 8:18:17 PM

Post# of 252496
<Would managed care/CMS pay for an expensive procedure that was tantamount to a diagnostic for more than 75% of the patients?>

The data that we have seen only talks about CD54 upregulation as a potency measure of the product at the time that it is manufactured. Let's not build on PGS' hypothesis that CD54 upregulation is a persistent patient characteristic that you can use for diagnosis yet until we see real data to support it.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up